Advances in Enhancing Hemocompatibility of Hemodialysis Hollow-Fiber Membranes
Source abstract
Abstract
Hemodialysis, the most common modality of renal replacement therapy, is critically required to remove uremic toxins from the blood of patients with end-stage kidney disease. However, the chronic inflammation, oxidative stress as well as thrombosis induced by the long-term contact of hemoincompatible hollow-fiber membranes (HFMs) contribute to the increase in cardiovascular diseases and mortality in this patient population. This review first retrospectively analyzes the current clinical and laboratory research progress in improving the hemocompatibility of HFMs. Details on different HFMs currently in clinical use and their design are described. Subsequently, we elaborate on the adverse interactions between blood and HFMs, involving protein adsorption, platelet adhesion and activation, and the activation of immune and coagulation systems, and the focus is on how to improve the hemocompatibility of HFMs in these aspects. Finally, challenges and future perspectives for improving the hemocompatibility of HFMs are also discussed to promote the development and clinical application of new hemocompatible HFMs. Graphical abstract
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dialysis and Renal Disease Management · Acute Kidney Injury Research · Membrane Separation Technologies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen XY, Gipson D, Gu HY, Hirth RA, Hutton D, Jin Y, Kapke A, Kurtz V, Li YT, McCullough K, Modi Z, Morgenstern H, Mukhopadhyay P, Pearson J, Pisoni R, Repeck K, Schaubel DE, Shamraj R, Steffick D, Turf M, Woodside KJ, Xiang J, Yin MG, Zhang XS, Shahinian V. Us renal data system annual data report: epidemiology of kidney disease in the united states. Am J Kidney Dis. 2020. https://doi.org/10.1053/j.ajkd.2019.09.003.10.1053/j.ajkd.2019.09.003 ↗
2. Yang C, Yang Z, Wang J, Wang H-Y, Su Z, Chen R, Sun X, Gao B, Wang F, Zhang L, Jiang B, Zhao M-H. China kidney disease network work g estimation of prevalence of kidney disease treated with dialysis in china: a study of insurance claims data. Am J Kidney Dis. 2021;77:889.10.1053/j.ajkd.2020.11.021 ↗
3. Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, Jindal K, Salako BL, Rateb A, Osman MA, Qarni B, Saad S, Lunney M, Wiebe N, Johnson DW. Assessment of global kidney health care status. JAMA-J Am Med Assoc. 1864;2017:317.
4. Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2012;81:1044.10.1038/ki.2012.39 ↗
5. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv JC, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 1975;2015:385.
6. Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018;14:394.10.1038/s41581-018-0002-x ↗
7. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 2005;1999:56.
8. Lysaght MJ. Evolution of hemodialysis membranes. In: Bonomini V, Berland Y, editors. Dialysis membranes: Structure and predictions Contributions to nephrology. Basel: S Karger AG; 1995. p. 1.
9. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS. Hemodialysis leukopenia-pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977;59:879.10.1172/JCI108710 ↗
10. Hakim RM, Fearon DT, Lazarus JM. Biocompatibility of dialysis membranes-effects of chronic complement activation. Kidney Int. 1984;26:194.10.1038/ki.1984.155 ↗
11. Kreusser W, Reiermann S, Vogelbusch G, Bartual J, Schulze-Lohoff E. Effect of different synthetic membranes on laboratory parameters and survival in chronic haemodialysis patients. NDT Plus. 2010;3: i12.
12. Irfan M, Idris A. Overview of pes biocompatible/hemodialysis membranes: Pes-blood interactions and modification techniques. Mater Sci Eng C-Mater Biol Appl. 2015;56:574.10.1016/j.msec.2015.06.035 ↗
13. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney Int. 2003;63:353.10.1046/j.1523-1755.2003.00741.x ↗
14. Tielemans C, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanherweghem JL. Anaphylactoid reactions during hemodialysis on an69 membranes in patients receiving ace inhibitors. Kidney Int. 1990;38:982.10.1038/ki.1990.301 ↗
15. Kohlova M, Amorim CG, Araujo A, Santos-Silva A, Solich P, Montenegro M. The biocompatibility and bioactivity of hemodialysis membranes: Their impact in end-stage renal disease. J Artif Organs. 2019;22:14.10.1007/s10047-018-1059-9 ↗
16. Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019;32:58.10.1111/sdi.12745 ↗
17. Claudel SE, Miles LA, Murea M. Anticoagulation in hemodialysis: a narrative review. Semin Dial. 2020;34:103.10.1111/sdi.12932 ↗
18. Song X, Ji HF, Li YP, Xiong YQ, Qiu L, Zhong R, Tian M, Kizhakkedathu JN, Su BH, Wei Q, Zhao WF, Zhao CS. Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres. Nat Biomed Eng. 2021;5:1143.10.1038/s41551-020-00673-x ↗
19. Mollahosseini A, Abdelrasoul A, Shoker A. A critical review of recent advances in hemodialysis membranes hemocompatibility and guidelines for future development. Mater Chem Phys. 2020;248: 122911.10.1016/j.matchemphys.2020.122911 ↗
20. Liu Y, Li GL, Han Q, Lin HB, Li Q, Hua J, Liu F. Anticoagulant dialyzer with enhanced ca2+ chelation and hydrophilicity for heparin free hemodialysis. J Membr Sci. 2020;604: 118082.
21. Hedayati M, Neufeld MJ, Reynolds MM, Kipper MJ. The quest for blood-compatible materials: Recent advances and future technologies. Mater Sci Eng R-Rep. 2019;138:118.10.1016/j.mser.2019.06.002 ↗
22. Yu XF, Zhu YD, Zhang TH, Deng L, Li PY, Wang XF, Hsiao BS. Heparinized thin-film composite membranes with sub-micron ridge structure for efficient hemodialysis. J Membr Sci. 2020;599: 117706.
23. Jaffer IH, Weitz JI. The blood compatibility challenge. Part 1: Blood-contacting medical devices: the scope of the problem. Acta Biomater. 2019;94:2.10.1016/j.actbio.2019.06.021 ↗
24. Ronco C, Ghezzi PM, Bowry SK. Membranes for hemodialysis. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, editors. Replacement of renal function by dialysis. Netherlands, Dordrecht: Springer; 2004. p. 301.10.1007/978-1-4020-2275-3_13 ↗
25. Sunohara T, Masuda T. Cellulose triacetate as a high-performance membrane. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-performance membrane dialyzers. Karger, Basel: Contributions to nephrology; 2011. p. 156.10.1159/000329055 ↗
26. Bowry SK, Gatti E, Vienken J. Contribution of polysulfone membranes to the success of convective dialysis therapies. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-performance membrane dialyzers. Karger, Basel: Contributions to nephrology; 2011. p. 110.10.1159/000328960 ↗
27. Thomas M, Moriyama K, Ledebo I. An69: Evolution of the world’s first high permeability membrane. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-performance membrane dialyzers. Karger, Basel: Contributions to nephrology; 2011. p. 119.10.1159/000328961 ↗
28. Sakai Y. Polymethylmethacrylate membrane with a series of serendipity. 2011 In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, (eds). High-performance membrane dialyzers. Contributions to nephrology,. pp. 137.10.1159/000329052 ↗
29. Li Y, Sun P, Chang K, Yang M, Deng N, Chen S, Su B. Effect of continuous renal replacement therapy with the oxiris hemofilter on critically ill patients: a narrative review. J Clin Med. 2022;11:6719.10.3390/jcm11226719 ↗
30. Krieter DH, Lemke HD. Polyethersulfone as a high-performance membrane. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-performance membrane dialyzers. Karger, Basel: Contributions to nephrology; 2011. p. 130.10.1159/000329051 ↗
31. Zhang Z, Yang T, Li Y, Li J, Yang Q, Wang L, Jiang L, Su B. Effects of expanded hemodialysis with medium cut-off membranes on maintenance hemodialysis patients: a review. Membranes. 2022;12:253.10.3390/membranes12030253 ↗
32. Lorenzin A, Golino G, de Cal M, Pajarin G, Savastano S, Lupi A, Sandini A, Fiorin F, Ronco C. Flow dynamic analysis by contrast-enhanced imaging techniques of medium cutoff membrane hemodialyzer. Blood Purif. 2022;51:138.10.1159/000516411 ↗
33. Jonny J, Teressa M. Expanded hemodialysis: a new concept of renal replacement therapy. J invest med. 2023;71:38.10.1136/jim-2022-002431 ↗
34. Hung YH, Lai TS, Belmouaz M, Tu YC, Lai CF, Lin SL, Chen YM. Effects of medium cut-off polyarylethersulfone and polyvinylpyrrolidone blend membrane dialyzers in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. Membranes. 2022;12:443.10.3390/membranes12050443 ↗
35. Weiner DE, Falzon L, Skoufos L, Bernardo A, Beck W, Xiao M, Tran H. Efficacy and safety of expanded hemodialysis with the theranova 400 dialyzer: a randomized controlled trial. Clin J Am Soc Nephrol: CJASN. 2020;15:1310.10.2215/CJN.01210120 ↗
36. Kim YG, Lee SH, Jung SW, Jung GT, Lim HJ, Kim KP, Jo YI, Jin K, Moon JY. The medium cut-off membrane does not lower protein-bound uremic toxins. Toxins. 2022;14:779.10.3390/toxins14110779 ↗
37. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Renal Nutr. 2012;22:149.10.1053/j.jrn.2011.10.020 ↗
38. Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol. 2011;7:499.10.1038/nrneph.2011.88 ↗
39. Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. Semin Dial. 2000;13:181.10.1046/j.1525-139X.2000.00052.x ↗
40. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11:178.10.1111/j.1542-4758.2007.00166.x ↗
41. Davenport A. Anticoagulation for continuous renal replacement therapy. In: Ronco C, Bellomo R, Brendolan A, editors. Sepsis, kidney and multiple organ dysfunction. Karger, Basel: Contributions to nephrology; 2004. p. 228.10.1159/000078891 ↗
42. Wright MJ, Woodrow G, Umpleby S, Hull S, Brownjohn AM, Turney JH. Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does-not influence heparin requirements in hemodialysis. Am J Kidney Dis. 1999;34:36.10.1016/S0272-6386(99)70105-8 ↗
43. Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M. Assessment of heparin binding to the an69 st hemodialysis membrane: I. Preclin stud Asaio J. 2005;51:342.
44. Laville M, Dorval M, Ros JF, Fay R, Cridlig J, Nortier JL, Juillard L, Debska-Slizien A, Lorente LF, Thibaudin D, Franssen C, Schulz M, Moureau F, Loughraieb N, Rossignol P. Results of the hepzero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 2014;86:1260.10.1038/ki.2014.225 ↗
45. Skagerlind MSE, Stegmayr BG. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis. Eur J Clin Pharmacol. 2018;74:267.10.1007/s00228-017-2389-x ↗
46. Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007;49:642.10.1053/j.ajkd.2007.02.001 ↗
47. François K, De Clerck D, Tonnelier A, Cambier ML, Orlando C, Jochmans K, Cools W, Wissing KM. Dialyzer performance during hemodialysis without systemic anticoagulation using a heparin-grafted dialyzer combined with a citrate-enriched dialysate: results of the randomized crossover noninferiority evocit study. Am J Kidney Dis. 2022;79:79.10.1053/j.ajkd.2021.04.004 ↗
48. Sosa MA, Balk EM, Lau J, Liangos O, Balakrishnan VS, Madias NE, Pereira BJG, Jaber BL. A systematic review of the effect of the excebrane dialyser on biomarkers of lipid peroxidation. Nephrol Dial Transplant. 2006;21:2825.10.1093/ndt/gfl376 ↗
49. Giardini O, Tacconegallucci M, Lubrano R, Ricciarditenore G, Bandino D, Silvi I, Ruberto U, Casciani CU. Evidence of red-blood-cell membrane lipid-peroxidation in hemodialysis-patients. Nephron. 1984;36:235.10.1159/000183160 ↗
50. Claster S, Chiu DTY, Quintanilha A, Lubin B. Neutrophils mediate lipid-peroxidation in human red-cells. Blood. 1984;64:1079.10.1182/blood.V64.5.1079.1079 ↗
51. Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT. Effects of vitamin c infusion and vitamin e-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006;69:706.10.1038/sj.ki.5000109 ↗
52. Kirmizis D, Papagianni A, Belechri AM, Memmos D. Effects of vitamin e-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant. 2011;26:2296.10.1093/ndt/gfq715 ↗
53. Rodriguez-Ribera L, Corredor Z, Silva I, Diaz JM, Ballarin J, Marcos R, Pastor S, Coll E. Vitamin e-coated dialysis membranes reduce the levels of oxidative genetic damage in hemodialysis patients. Mutat Res Genet Toxicol Environ Mutagen. 2017;815:16.10.1016/j.mrgentox.2017.01.003 ↗
54. Zhang Y, Gao W, Li X. Vitamin e-coated dialyzer alleviates erythrocyte deformability dysfunction in patients with end-stage renal disease undergoing hemodialysis. Exp Ther Med. 2022;24:480.10.3892/etm.2022.11407 ↗
55. Yang SK, Xiao L, Xu B, Xu XX, Liu FY, Sun L. Effects of vitamin e-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: A systematic review and meta-analysis. Ren Fail. 2014;36:722.10.3109/0886022X.2014.890858 ↗
56. Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 1984;311:878.10.1056/NEJM198410043111403 ↗
57. Kabanda A, Jadoul M, Pochet JM, Lauwerys R, Destrihou CV, Bernard A. Determinants of the serum concentrations of low-molecular-weight proteins in patients on maintenance hemodialysis. Kidney Int. 1994;45:1689.10.1038/ki.1994.221 ↗
58. Vanholder RC, Ringoir SM. Intradialytic body-weight changes and dialyzer pore-size as main contributing factors to the evolution of beta-2-microglobulin in dialysis. Blood Purif. 1990;8:32.10.1159/000169922 ↗
59. Kalocheretis P, Vlamis I, Belesi C, Makriniotou I, Zerbala S, Savidou E, Zorbas S, Arvanitis N, Iatrou C. Residual blood loss in single use dialyzers: Effect of different membranes and flux. Int J Artif Organs. 2006;29:286.10.1177/039139880602900306 ↗
60. Liu S, Shi W, Liang X, Su Y, Liang Y, Zhang B, Ye Z, Xu L, Xia Y, He C, Ma J, Tao Y, Ye H, Li H. Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration. Blood Purif. 2010;29:375.10.1159/000314649 ↗
61. Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer a randomized crossover comparison between cellulose triacetate and polysulphon. ASAIO J. 1995;41:215.10.1097/00002480-199541020-00018 ↗
62. Yamashita AC. Commercially available high-performance membrane dialyzers and several special kinds on the japanese market. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. high-performance membrane dialyzers. KARGER, Basel: Contributions to nephrology; 2011. p. 191.10.1159/000329634 ↗
63. Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins - a cross-over trial. Nephrol Dial Transplant. 1998;13:1452.10.1093/ndt/13.6.1452 ↗
64. Thijs A, Grooteman MPC, Zweegman S, Nube MJ, Huijgens PC, Stehouwer CDA. Platelet activation during haemodialysis: comparison of cuprammonium rayon and polysulfone membranes. Blood Purif. 2007;25:389.10.1159/000108628 ↗
65. Opatrny K, Sulkova S, Lopot F, Vit L, Valek A. Clinical-study of high-flux cuprammonium rayon hemodialysis membranes. Artif Organs. 1993;17:971.10.1111/j.1525-1594.1993.tb03178.x ↗
66. Chanard J, Brunois JP, Melin JP, Lavaud S, Toupance O. Long-term results of dialysis therapy with a highly permeable membrane. Artif Organs. 1982;6:261.10.1111/j.1525-1594.1982.tb01671.x ↗
67. Jindal KK, McDougall J, Woods B, Nowakowski L, Goldstein MB. A study of the basic principles determining the performance of several high-flux dialyzers. Am J Kidney Dis. 1989;14:507.10.1016/S0272-6386(89)80151-9 ↗
68. Nakano A. Ethylene vinyl alcohol co-polymer as a high-performance membrane: An evoh membrane with excellent biocompatibility. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, editors. High-performance membrane dialyzers. Basel, Karger: Contributions to nephrology; 2011. p. 164.10.1159/000329056 ↗
69. Malard B, Florens N, Lambert C, Juillard L. Adsorption as a contributor for inflammatory mediators removal by different hemofiltration membranes: a pilot study. Artif Organs. 2017;41:545.10.1111/aor.12785 ↗
70. Brunet P, Frances J, Vacher-Coponat H, Jaubert D, Lebrun G, Gondouin B, Duval A, Berland Y. Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (an69st and polysulfone f60). Int J Artif Organs. 2011;34:1165.10.5301/ijao.5000033 ↗
71. Huang J, Yi B, Li AM, Zhang H. Effects of vitamin e-coated dialysis membranes on anemia, nutrition and dyslipidemia status in hemodialysis patients: a meta-analysis. Ren Fail. 2015;37:398.10.3109/0886022X.2014.1001281 ↗
72. Panichi V, Rosati A, Paoletti S, Ferrandello P, Migliori M, Beati S, Bernabini G, Daini R, Casani A, Angelini D, Parrini M, Rossi A, Petrone I, Barsotti G, Donadio C, Donati G, Grazi G, Rizza GM, Garosi G, Sansoni E, Braccagni B, Sidoti A, Boracelli D, Biagioli M, Moriconi L, Finato V, Mannarino A, Grimaldi C, Pansa F, Imperiali P, Mura C, Bianchi S, Bigazzi R. A vitamin e-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: Results of a randomized cross-over multicenter trial. Blood Purif. 2011;32:7.10.1159/000321369 ↗
73. Gura V, Rivara MB, Bieber S, Munshi R, Smith NC, Linke L, Kundzins J, Beizai M, Ezon C, Kessler L, Himmelfarb J. A wearable artificial kidney for patients with end-stage renal disease. JCI Insight. 2016;1:86397.10.1172/jci.insight.86397 ↗
74. Luo J, Fan JB, Wang ST. Recent progress of microfluidic devices for hemodialysis. Small. 2020;16:1904076.10.1002/smll.201904076 ↗
75. Fissell WH, Roy S, Davenport A. Achieving more frequent and longer dialysis for the majority: Wearable dialysis and implantable artificial kidney devices. Kidney Int. 2013;84:256.10.1038/ki.2012.466 ↗
76. Nicolau DV. A model of protein adsorption to solid surfaces from solution. In: Bornhop DJ, Dunn DA, Mariella RP, Murphy CJ, Nicolau DV, Nie S et al., editors. Biomedical nanotechnology architectures and applications. Proceedings of spie. Bellingham: Spie-Int Soc Optical Engineering; 2002. pp. 1.10.1117/12.472083 ↗
77. Brash JL, Horbett TA, Latour RA, Tengvall P. The blood compatibility challenge. Part 2: Protein adsorption phenomena governing blood reactivity. Acta Biomater. 2019;94:11.10.1016/j.actbio.2019.06.022 ↗
78. Wei Q, Becherer T, Angioletti-Uberti S, Dzubiella J, Wischke C, Neffe AT, Lendlein A, Ballauff M, Haag R. Protein interactions with polymer coatings and biomaterials. Angew Chem-Int Edit. 2014;53:8004.10.1002/anie.201400546 ↗
79. Ji HF, Xu H, Jin LQ, Song X, He C, Liu XL, Xiong L, Zhao WF, Zhao CS. Surface engineering of low-fouling and hemocompatible polyethersulfone membranes via in-situ ring-opening reaction. J Membr Sci. 2019;581:373.10.1016/j.memsci.2019.03.082 ↗
80. Zhao CS, Xue JM, Ran F, Sun SD. Modification of polyethersulfone membranes - a review of methods. Prog Mater Sci. 2013;58:76.10.1016/j.pmatsci.2012.07.002 ↗
81. Schmaier AH. The contact activation and kallikrein/kinin systems: Pathophysiologic and physiologic activities. J Thromb Haemost. 2016;14:28.10.1111/jth.13194 ↗
82. Arvidsson S, Askendal A, Tengvall P. Blood plasma contact activation on silicon, titanium and aluminium. Biomaterials. 2007;28:1346.10.1016/j.biomaterials.2006.11.005 ↗
83. Ahmad AL, Abdulkarim AA, Ooi BS, Ismail S. Recent development in additives modifications of polyethersulfone membrane for flux enhancement. Chem Eng J. 2013;223:246.10.1016/j.cej.2013.02.130 ↗
84. Horbett TA. Fibrinogen adsorption to biomaterials. J Biomed Mater Res Part A. 2018;106:2777.10.1002/jbm.a.36460 ↗
85. Rabe M, Verdes D, Seeger S. Understanding protein adsorption phenomena at solid surfaces. Adv Colloid Interface Sci. 2011;162:87.10.1016/j.cis.2010.12.007 ↗
86. Fagerstam LG, Frostellkarlsson A, Karlsson R, Persson B, Ronnberg I. Biospecific interaction analysis using surface-plasmon resonance detection applied to kinetic binding-site and concentration analysis. J Chromatogr. 1992;597:397.10.1016/0021-9673(92)80137-J ↗
87. Elwing H, Askendal A, Lundstrom I. Competition between adsorbed fibrinogen and high-molecular-weight kininogen on solid-surfaces incubated in human-plasma (the vroman effect)-influence of solid-surface wettability. J Biomed Mater Res. 1987;21:1023.10.1002/jbm.820210808 ↗
88. Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces. Blood. 1986;68:355.10.1182/blood.V68.2.355.355 ↗
89. Yang LW, Han LL, Liu Q, Xu YG, Jia LY. Galloyl groups-regulated fibrinogen conformation: understanding antiplatelet adhesion on tannic acid coating. Acta Biomater. 2017;64:187.10.1016/j.actbio.2017.09.034 ↗
90. Matsumoto M. Spread monolayers of a water-soluble protein (ferritin) and its 2-dimensional and 3-dimensional arrays. Langmuir. 1994;10:3922.10.1021/la00023a002 ↗
91. Norde W. Driving forces for protein adsorption at solid surfaces. Macromol Symp. 1996;103:5.10.1002/masy.19961030104 ↗
92. Engel MFM, Visser A, van Mierlo CPM. Conformation and orientation of a protein folding intermediate trapped by adsorption. Proc Natl Acad Sci U S A. 2004;101:11316.10.1073/pnas.0401603101 ↗
93. Lu JR, Zhao XB, Yaseen M. Biomimetic amphiphiles: biosurfactants. Curr Opin Colloid Interface Sci. 2007;12:60.10.1016/j.cocis.2007.05.004 ↗
94. Gorbet M, Sperling C, Maitz MF, Siedlecki CA, Werner C, Sefton MV. The blood compatibility challenge. Part 3: material associated activation of blood cascades and cells. Acta Biomater. 2019;94:25.10.1016/j.actbio.2019.06.020 ↗
95. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev. 2011;25:155.10.1016/j.blre.2011.03.002 ↗
96. Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood. 2016;128:753.10.1182/blood-2016-05-718114 ↗
97. Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2017;37:E13.10.1161/ATVBAHA.117.308564 ↗
98. Fredenburgh JC, Gross PL, Weitz JI. Emerging anticoagulant strategies. Blood. 2017;129:147.10.1182/blood-2016-09-692996 ↗
99. Ji HF, Xiong L, Shi ZQ, He M, Zhao WF, Zhao CS. Engineering of hemocompatible and antifouling polyethersulfone membranes by blending with heparin-mimicking microgels. Biomater Sci. 2017;5:1112.10.1039/C7BM00196G ↗
100. Wang LR, He M, Gong T, Zhang X, Zhang LC, Liu T, Ye W, Pan CJ, Zhao CS. Introducing multiple bio-functional groups on the poly(ether sulfone) membrane substrate to fabricate an effective antithrombotic bio-interface. Biomater Sci. 2017;5:2416.10.1039/C7BM00673J ↗